高级检索
    王孟昭. 基于KEYNOTE-042研究PD-L1≥1%的NSCLC患者使用帕博利珠单抗或化疗作为一线治疗的5年结局[J]. 循证医学, 2023, 23(4): 203-207. DOI: 10.12019/j.issn.1671-5144.2023.04.003
    引用本文: 王孟昭. 基于KEYNOTE-042研究PD-L1≥1%的NSCLC患者使用帕博利珠单抗或化疗作为一线治疗的5年结局[J]. 循证医学, 2023, 23(4): 203-207. DOI: 10.12019/j.issn.1671-5144.2023.04.003
    shu
    WANG Meng-zhao. First-Line Pembrolizumab Versus Chemotherapy in PD-L1 Positive Non-Small-Cell Lung Cancer: 5-Year Outcomes From the KEYNOTE-042 Study[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 203-207. DOI: 10.12019/j.issn.1671-5144.2023.04.003
    Citation: WANG Meng-zhao. First-Line Pembrolizumab Versus Chemotherapy in PD-L1 Positive Non-Small-Cell Lung Cancer: 5-Year Outcomes From the KEYNOTE-042 Study[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 203-207. DOI: 10.12019/j.issn.1671-5144.2023.04.003
    shu

    基于KEYNOTE-042研究PD-L1≥1%的NSCLC患者使用帕博利珠单抗或化疗作为一线治疗的5年结局

    First-Line Pembrolizumab Versus Chemotherapy in PD-L1 Positive Non-Small-Cell Lung Cancer: 5-Year Outcomes From the KEYNOTE-042 Study

      摘要
      • HTML全文
      • 参考文献(14)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回